Elevated ALT Causes: 7 Common Reasons for High Liver Enzymes

Non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects one in four people worldwide and is characterized by excessive triglyceride accumulation in hepatocytes. The condition follows a two-hit hypothesis where initial fat accumulation is reversible, but a second hit triggers inflammation, oxidative stress, and activation of hepatic stellate cells, leading to fibrosis and potentially cirrhosis. Key risk factors include insulin resistance, high fructose intake, and gut-liver axis dysfunction, while the single most critical factor determining disease progression is fibrosis development.

Non-alcoholic fatty liver disease (NAFLD) involves >5% hepatic fat without injury/fibrosis, while non-alcoholic steatohepatitis (NASH) adds hepatocyte ballooning, inflammation, and fibrosis. Fibrosis staging progresses from minimal pericentral/perisinusoidal fibrosis (Stage 1) through periportal fibrosis (Stage 2), bridging fibrosis (Stage 3), to cirrhosis (Stage 4). Fibrosis progression drives disease severity, with bridging fibrosis to cirrhosis causing dramatic survival reduction, increased decompensation, and hepatocellular carcinoma risk. In the US, 60-80 million have NAFLD, 15-20 million have NASH, with 20-30% progressing over three years. One-fifth are fast progressors reaching cirrhosis in 10 years. Cirrhosis carries 30-40% mortality risk. Pathophysiology involves peripheral lipolysis delivering free fatty acids causing lipotoxicity, mitochondrial dysfunction, ER stress, apoptosis, macrophage activation, and hepatic stellate cell transformation into myofibroblasts depositing collagen.

The progression of non-alcoholic fatty liver disease follows a continuum: Initially, there may be minimal fatty infiltrate without clinical attention. Over time, this can lead to acute hepatitis (inflammation of the liver due to abnormal substances). If this inflammation persists chronically over many years, continued fat accumulation and inflammation can result in scar tissue formation in the liver, which is known as cirrhosis. This progression can lead to significant long-term morbidity.

NAFLD (non-alcoholic fatty liver disease) is the most common liver disease and leading cause of cirrosis. Visual identification shows normal liver as reddish while fatty liver appears orange with visible fat droplets. NAFLD presents between fourth and sixth decades, more common in women, with 75% of type 2 diabetes patients developing fatty liver. Progression stages include simple steatosis (benign, reversible with lifestyle changes), steatohepatitis (inflammation, ballooning degeneration, Mallory bodies), and cirrosis (1-2% progress over 15-20 years). The disease carries 2-5% annual risk of hepatocellular carcinoma. Pathophysiology involves insulin resistance driving hepatic de novo lipogenesis, increased free fatty acids, and triglyceride accumulation. The first hit theory describes how excess fructose and refined sugars alter adipocyte metabolism, generating cytokines that activate macrophages and increase free fatty acid flux to the liver. The second hit theory explains progression to steatohepatitis through oxidative stress, mitochondrial dysfunction, and accumulation of toxic metabolites (ceramides, diacylglycerol, oxidized cholesterol) causing hepatocyte death and inflammation.

Drug-Induced Liver Injury (DILI) is liver damage caused by medications including prescription drugs, supplements, and herbal products. The liver, weighing 1.4-1.6 kg in adults, performs critical functions including protein synthesis, metabolism, and drug detoxification. DILI occurs through two mechanisms: intrinsic (predictable toxicity like acetaminophen) and idiosyncratic (unpredictable, immune-mediated). Risk factors include genetics, age, gender, obesity, diabetes, HIV, alcohol, and smoking. Over 60% of cases involve antibiotics and antiepileptics, with common culprits including amiodarone, fluoroquinolones, and NSAIDs.

Drug-induced liver injury (DILI) is liver damage caused by any pharmaceutical agent, including prescription medications, biologically active supplements, and phytoproducts. DILI is a leading cause of acute liver failure in developed countries, with approximately 19 cases per 100,000 population and 4.5% of hospitalized patients. A critical statistic is that 50% of DILI cases are associated with supplements and phytoproducts. DILI occurs through three mechanisms: direct dose-dependent damage (predictable, e.g., acetaminophen), idiosyncratic non-dose-dependent injury (genetically determined, e.g., amoxicillin-clavulanate), and indirect immune-mediated effects (common in oncology with checkpoint inhibitors). The 2025 clinical guidelines provide standardized diagnostic and management protocols.

Herbal and dietary supplements now cause increasing DILI cases, representing a major public health concern. Unlike prescription drugs, supplements face no FDA safety testing before market, leading to widespread labeling inaccuracies and contamination. Analysis reveals half of tested supplements either lack labeled ingredients or contain undisclosed pharmaceutical compounds. Case examples include 'Tomoxilone' containing tamoxifen and OxyElite Pro containing DMAA, which caused multiple liver injuries and deaths leading to manufacturer prosecution. Green tea extract causes hepatocellular DILI with jaundice, predominantly in women, with strong HLA-B*35:01 association. Kratom use is rising dramatically with corresponding increases in DILI cases. LiverTox.org serves as an invaluable clinical resource with over 1,300 entries providing case presentations, injury patterns, pathology, and references for each drug. Key take-home messages emphasize that DILI is common with mild elevations but severe injury is rare; genetic risk factors exist primarily in HLA regions; diagnosis remains challenging requiring exclusion of other causes; herbal supplements are increasingly important causes often mislabeled or contaminated; and LiverTox.org provides essential clinical resources for diagnosis and management.

DILI risk factors include age (typically 18-64 years, higher risk in elderly due to comorbidities and polypharmacy), gender (more common in women), genetic predisposition (HLA associations, particularly with amoxicillin-clavulanate), comorbidities (obesity, diabetes, metabolic syndrome), environmental factors (smoking, alcohol consumption), and drug characteristics (lipophilicity, biochemistry). Mechanisms include direct hepatotoxicity (dose-related, short latency, examples: acetaminophen, aspirin), idiosyncratic hepatotoxicity (not dose-related, unpredictable, examples: amoxicillin-clavulanate, isoniazid), and indirect hepatotoxicity (immune-mediated, examples: antineoplastic agents).

A dangerous misconception is that OTC drugs are safe just because they don't need prescriptions. OTC drugs are real drugs with real effects and risks. Misuse is common—exceeding maximum daily acetaminophen dose (often unintentionally by taking multiple products containing it) can cause severe liver damage or failure. OTC can also have significant interactions with prescription drugs. Herbal supplements and dietary supplements are even less regulated—under DSHEA, manufacturers don't have to prove safety or efficacy to FDA before marketing, only responsible for ensuring product safety and label accuracy. FDA generally only acts after products prove unsafe.

Lifestyle modifications are the mainstay of NAFLD treatment. Weight loss targets correlate with benefits: 5% loss improves hepatic fat; 7% improves inflammation; 10% improves portal inflammation and early fibrosis. Recommended approach: 500-1000 caloric deficit daily plus moderate exercise. Mediterranean diet shows superior benefits compared to high-fat low-carb diets, even without weight loss. Alcohol: heavy consumption (>14 drinks/week men, >7 women) should be avoided; daily consumption discouraged regardless of amount. Pharmacologic options: Vitamin E (800 units/day for non-diabetic NASH) reduces transaminases but carries mortality risk above 800 units and prostate cancer concerns. Pioglitazone may help diabetic NASH patients with metformin resistance but concerns about weight gain and heart failure exist.

Two evidence-based approaches for NAFLD management are vitamin D supplementation and coffee consumption. Vitamin D deficiency affects 73.7% of elderly patients with nutritional deficiencies and directly contributes to liver fat accumulation through reduced microsomal 60 protein. Coffee consumption reduces NAFLD risk and disease progression, with caffeine providing antioxidant and anti-inflammatory benefits. For liver health, consume regular (not decaffeinated) coffee without additives. Recommended intake is 3+ cups daily for general health, 4-6 cups for NAFLD patients, reducing fibrosis risk by 43-49%.

Lifestyle modification is the cornerstone of NAFLD/NASH treatment, with evidence showing that dietary changes, physical activity, and weight reduction can reverse liver damage at all disease stages; specifically, achieving 5-10% weight reduction through a combination of Mediterranean-style diet and regular physical activity significantly improves steatosis and fibrosis, while avoiding ultra-processed foods, excessive fructose, and saturated fats further supports liver health and reduces hepatocellular carcinoma risk.

Combination interventions (diet plus exercise) are most effective for NAFLD. Patients should aim for 5-10% body weight loss, with higher targets for NASH. Total energy intake matters more than specific macronutrient composition, though low-carb diets may show short-term advantages. Aerobic and resistance exercise are equally effective. For plant-based diets, current evidence is limited to observational studies showing that healthy plant-based diets reduce NAFLD risk (21% lower risk in highest tertile), while unhealthy plant-based diets increase risk. Mediterranean diet composition is recommended alongside weight loss, though most studies come from Spain/Italy with potential regional bias. Both Mediterranean and low-fat diets reduced hepatic fat in a comparative study, though neither achieved optimal weight loss goals.

From a food-based perspective, dietary recommendations for liver health include: choosing plant-based sources of fats over animal-based saturated fats (replacing beef, meat, and butter with olive oil, rapeseed oil, nuts, seeds, and marine omega-3s); emphasizing whole grains, legumes, and tubers over refined carbohydrates; and selecting vegetable oils and low-fat dairy products. The Danish nutrition guidelines provide practical guidance: eat plant-rich varied diets, consume more vegetables and fruit, choose legumes and fish over meat, eat whole grain foods, select vegetable oils and low-fat dairy, limit sweet salty and fatty foods, and drink water. Research suggests meal frequency may influence liver fat accumulation, particularly in overfeeding contexts—a six-week study found significantly greater liver fat increases when excess calories were consumed as snacks between meals versus as three main meals. Beyond diet, physical activity influences liver fat through substrate utilization and visceral fat reduction, while sleep deprivation increases caloric intake (~300 calories/day more) and visceral fat accumulation, indirectly affecting liver fat.